Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives

News

 26th February 2013
Aptar Pharma

Aptar Pharma's Twister®: A Versatile DPI for Fast Growing Markets

Global solution provider of innovative and proven aerosol, injection and spray delivery systems for prescription drugs, Aptar Pharma Prescription Division presented Twister®, its latest Dry Powder Inhaler innovation, at the Pharmapack Europe tradeshow held in Paris, France, between February 13th to February 14th, 2013.

Expansion of asthma and COPD treatments in fast growing markets

It is estimated by the World Health Organization (WHO) that worldwide, some 300 million people suffer from asthma, and 240 million people suffer from chronic obstructive pulmonary disease (COPD).

The cost of these diseases to the US healthcare system is estimated at $50.2 billion for asthma, and $32.1 billion for COPD.

The majority of asthma and COPD treatment sales in the US and Europe come from drugs delivered by Dry Powder Inhalers (DPIs). In the fast growing markets of Asia and Latin America, asthma has been treated predominantly with pMDIs, which in many countries are still considered to be more cost-effective than DPIs.

DPIs represent 50% of the total asthma/COPD market by value worldwide, with most growth seen historically in the US and Europe. Aptar Pharma is anticipating that this DPI growth trend will spread to fast growing markets, driven by the healthcare reforms that are making asthma and COPD diagnosis and medication more available to patients.

Expectations of patients and pneumologists regarding DPIs in fast growing markets have evolved. They are now increasingly focusing on convenience and ease of use, favoring a compact and simple design. DPIs should be of good quality to ensure a long life, and be recyclable when they need to be replaced. (source: Aptar Pharma’s latest patient-focused studies using DPIs, performed in China).

Key benefits of Aptar Pharma’s Twister®, a versatile affordable DPI for fast growing markets

Twister® is a new capsule-based DPI, designed specifically to address unmet medical needs in fast growing markets. During its development by a dedicated Aptar Pharma multi-disciplinary technical team, Twister® was tested and validated with a number of different dry powder drug formulations. Twister® has a simple and robust design with few components, making it cost-attractive for asthma and COPD treatments in fast growing markets.

Twister® is designed to be patient-friendly and easy to use, allowing patients easy access to their medication in three simple steps: Insert, Twist and Inhale. To help improve patient compliance with the prescribed treatment, Twister® is transparent, allowing the capsule and powder to be seen in the device as they are processed. In addition to these visual cues, the patient is also guided by audible feedback during inhalation.

To meet demand in fast growing markets

Development of Twister® by an international Aptar Pharma project team started in France and continued in China, where industrial manufacturing now takes place. Twister®, which is registered as a medical device by the sFDA, is molded and assembled in a class ISO 7 cleanroom at the Aptar Pharma state-of-the-art production facility in Suzhou, China.

Aptar Pharma was one of the pioneers of local drug delivery systems manufacturing in China, and was the first company licensed to manufacture spray and aerosol drug delivery devices for this market. Aptar Pharma Suzhou was opened in 1996 and produces pMDI metering valves and spray pumps for the Asian market. Manufacturing Twister® at the Suzhou facility is another step forward in Aptar Pharma’s global expansion and commitment to provide world class quality products, promoting better healthcare access worldwide.

Adam M. Shain gave a presentation on Twister® during Pharmapack Europe on February 14th 2013.

“Aptar Pharma is very pleased to present Twister® at Pharmapack Europe. This device is designed to fulfill regional needs for a simpler and cost effective solution to deliver dry powder to the lungs. Twister® is the latest member of our comprehensive range of drug delivery solutions, available worldwide for the pharmaceutical industry’s treatments of asthma and COPD”, states Adam M. Shain, Associate Director Business Development, Aptar Pharma Prescription Division.

For more information on Twister®, please contact us.

About Aptar Pharma

Aptar Pharma is part of the Aptargroup family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world. We provide our customers with a wide range of delivery technologies and analytical services backed by decade of proven expertise. For more information, visit www.aptar.com/pharma

Aptargroup (NYSE: ATR) is headquartered in the US and has manufacturing sites in North America, Europe, Asia and South America. For more information, visit www.aptar.com

Aptar Pharma Press Contacts

Elisa Eschylle, Events and Press relations manager Tel.: +33 (0)1 39 17 20 41 E-mail : elisa.eschylle@aptar.com

Marion Baschet Vernet, Press attaché Tel.: +44 (0)797 609 41 00 E-mail : mbvernet@gmail.com


 

Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |